Abstract: There is provided a pharmaceutical composition comprising lemborexant exhibiting a favorable dissolution profile by using a granular material having a 90% cumulative diameter (D90) of 64 ?m or less as a lemborexant active pharmaceutical ingredient.

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Abstract: The invention provides extended release formulations of proton pump inhibitor, such as an extended release formulation of rabeprazole, comprising an amount of rabeprazole between 30 and 90 mg rabeprazole and having an AUC of between 900 and 1750 ng*hr/mL and other properties.

Abstract: The present invention provides a pharmaceutical preparation to be dispersed before administration which has an adequate viscosity and a suitable flowability even when dispersed in a small amount of water and can be easily administered through an NG tube is provided. Specifically, the pharmaceutical preparation to be dispersed before administration contains active granules containing a pharmaceutically active substance having an average particle diameter of 5 mm or less and a thickening agent, and can be administered through an NG tube by dispersing in water before administration.

Abstract: Parts of a powdered medicine multi-dose administering device are assembled, powdered medicine is filled and assembly that is obtained is inspected all on an automatic production line to increase productivity while preventing the production of defective products. The powdered medicine multi-dose administering device is produced through automated steps of inserting a filter (12) in a filter-fitting portion (11a) of a container (10), inserting an inner cylinder (15) in the container body (10), filling the container with the powdered medicine through a ring-like opening between an opening in the upper part of the container and the inner cylinder, fitting an inner closure (19) to the container and to the inner cylinder, fitting a nozzle (20) to the container while coupling it to the inner cylinder, and inspecting the thus obtained assembly.

Abstract: An object of the present invention is to provide a pulsed-release preparation that achieves pulsed-release by coating the exterior of a core that contains a physiologically active substance and a disintegrant, with a controlled-release coating that contains a water-insoluble polymer and an enteric polymer, or a water-insoluble polymer and a water-soluble polymer, wherein a satisfactory pulsed-release can be achieved without increasing the amount of disintegrant in the core, in particular even in the low-water environment in the lower part of the digestive tract. The present invention provides a pulsed-release preparation comprising: 1) a core containing a physiologically active substance and a disintegrant; 2) an enteric coating that covers the core; and 3) a controlled-release coating that covers the enteric coating applied on the core and that contains a water-insoluble polymer and an enteric polymer or water-soluble polymer.

Abstract: The present invention provides a fluidized bed device for handling fine particles as a fluidized bed in a medicine manufacturing process, a cosmetic manufacturing process, a food manufacturing process, a chemical manufacturing process and the like, wherein influence of static electricity is suppressed, and a method for neutralizing the static electricity using that device. The fluidized bed device includes an X-ray irradiation unit for irradiating fine particles in the fluidized bed device with X-rays.

Abstract: A method of weighing an easily chargeable measured object able to remove the effects of static electricity to weigh a measured object by an accuracy of about 0.3 mg continuously with a good work efficiency. When using an electronic scale (10) provided with a weighing platform (11) and a weighing pan (12) able to move vertically by a very small distance with respect to the weighing platform to weight an easily chargeable measured object (14), the measured object is weighed in the state with a conductive frame (13) of a suitable size set on the weighing platform (11) around the weighing pan so as to surround the measured object placed on the weighing pan.

Abstract: A method of weighing an easily chargeable measured object able to remove the effects of static electricity to weigh a measured object by an accuracy of about 0.3 mg continuously with a good work efficiency. When using an electronic scale (10) provided with a weighing platform (11) and a weighing pan (12) able to move vertically by a very small distance with respect to the weighing platform to weight an easily chargeable measured object (14), the measured object is weighed in the state with a conductive frame (13) of a suitable size set on the weighing platform (11) around the weighing pan so as to surround the measured object placed on the weighing pan.

Abstract: Parts of a powdered medicine multi-dose administering device are assembled, powdered medicine is filled and assembly that is obtained is inspected all on an automatic production line to increase productivity while preventing the production of defective products. The powdered medicine multi-dose administering device is produced through automated steps of inserting a filter (12) in a filter-fitting portion (11a) of a container (10), inserting an inner cylinder (15) in the container body (10), filling the container with the powdered medicine through a ring-like opening between an opening in the upper part of the container and the inner cylinder, fitting an inner closure (19) to the container and to the inner cylinder, fitting a nozzle (20) to the container while coupling it to the inner cylinder, and inspecting the thus obtained assembly.